Venus Remedies Ltd has received Good Manufacturing Practices (GMP) accreditation for its 7 facilities including oncology liquid, oncology lyophilized, cephalosporin, carbapenem, cardiovascular, small volume infusion and other specialty injection from National Medicine and Poison Board (NMPB) Republic of Sudan.

As per the reports of CMS Sudan, existing Sudanese Pharmaceutical market amounts to approx USD 520 million which is growing at 11 percent annually and market is largely dependent upon imports. In the context of pharmacological group, the two major segments are anti infective 28.6% and CVS 13.7% contributing to a sum of 42.3% of the total market share. It is an opportunity for Venus Remedies to tap this huge market with unique and innovative products.

"Venus is now looking forward to serve Sudan which is the largest country in Africa. MENA (Middle East and North Africa) region is believed to be one of the stringent regulatory approval systems across the globe. Due to this only big pharma players will be our competitors for generic products," said Dr. Manu Chaudhary, JMD, Venus Remedies Ltd.

Venus Remedies is also in the process of seeking registration for products from all the seven facilities. The company has already filed 17 critical care product dossiers mainly in anti cancer and antibiotics.

The products for the market have been carefully selected by the company keeping in mind that Sudan is experiencing a burgeoning cancer epidemic that carries many challenges and are characteristic of developing countries. These include a high incidence of advanced, difficult-to-treat disease at presentation, and a high cancer burden that is related to infectious diseases.

The growth potential for this region looks to be very positive based on growth drivers like largest country in Africa with population of 42 million, growing economies in the region, high purchasing power, increased spend on healthcare facilities by governments, mandatory health insurance schemes and demographic trends like an increase in life expectancy, literacy rates and prevalence of life style related diseases like diabetes, cardiovascular, gastro and niche cancer , anti infective therapies. These therapies constitute around 35.7 percent of total pharma volume.

Sudan is the 10th country of African continent where Venus will have strong presence including Ethiopia, Kenya, Uganda, Botswana, Zimbabwe, Togo and South Africa. With this GMP Venus today possesses 13 international GMP certifications from different countries of the world including EU-GMP which is valid for entire Europe for its super specialty injectable manufacturing facilities.

The company has appointed one of the biggest pharmaceutical distributors in Sudan for the promotion of their products. The company is highly optimistic in making good sales from the very first year of registrations. The company also plans to register its research products Sulbactomax and Potentox in this market.